PBH:NYE-Prestige Brand Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 84.88

Change

-0.31 (-0.36)%

Market Cap

USD 2.60B

Volume

0.32M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Prestige Brands Holdings Inc is engaged in the marketing, sales and distribution of well-recognized, brand name OTC healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.78 (+0.50%)

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

+0.12 (+0.87%)

USD 43.37B
HLN Haleon plc

-0.08 (-0.80%)

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

+0.07 (+0.52%)

USD 11.49B
ELAN Elanco Animal Health

-0.11 (-0.98%)

USD 5.69B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.02 (+0.25%)

USD 3.63B
BHC Bausch Health Companies Inc

+0.67 (+10.29%)

USD 2.41B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

+0.01 (+3.14%)

USD 1.96M
EBS Emergent Biosolutions Inc

-0.13 (-1.63%)

N/A

ETFs Containing PBH

XST:CA iShares S&P/TSX Capped Co.. 2.87 % 0.61 %

-0.65 (0.63%)

CAD 0.25B
PSCH Invesco S&P SmallCap Heal.. 2.46 % 0.29 %

-0.94 (0.63%)

USD 0.19B
NDIA Global X Funds 0.00 % 0.00 %

+0.09 (+0.63%)

USD 0.02B
EMC Global X Funds 0.00 % 0.00 %

+0.17 (+0.63%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.70% 93% A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.70% 93% A 83% B
Trailing 12 Months  
Capital Gain 22.50% 79% B- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.50% 79% B- 75% C
Trailing 5 Years  
Capital Gain 100.19% 100% F 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.19% 100% F 84% B
Average Annual (5 Year Horizon)  
Capital Gain 19.43% 86% B+ 80% B-
Dividend Return 19.43% 86% B+ 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.48% 79% B- 53% F
Risk Adjusted Return 94.88% 100% F 93% A
Market Capitalization 2.60B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.00 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike